Turning crop waste into precision weapons against waterborne pathogens

Antimicrobial resistance and ecological disruption caused by broad-spectrum disinfectants have created an urgent need for precision strategies that remove harmful bacteria without damaging beneficial ...

Basilea and Prokaryotics enter collaboration to develop a novel broad-spectrum antifungal for the treatment of severe invasive infections

Allschwil, Switzerland, January 07, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed ...
Nasdaq

USDA and Genvor Scientists Publish Research Highlighting Broad-Spectrum Efficacy of Genvor’s Antimicrobial Peptides

CHAPEL HILL, NC / ACCESSWIRE / December 18, 2023 / Genvor Incorporated (OTCQB:GNVR) ("Genvor" or the "Company"), a developer of sustainable plant health solutions leveraging patented peptides, ...
European Medical Journal

Ants Could Inspire the Next Generation of Antibiotics

Ants produce diverse, targeted antimicrobial compounds that inhibit drug-resistant pathogens, offering insights for new ...
Morningstar

Enviro Tech Launches Peragreen(R) 26WW: Smart Microbial Control for Medium - to Large-Scale Municipal Wastewater Systems

Fast-acting, EPA-registered PAA solution for efficient microbial reduction-cost-effective and retrofit-ready. MODESTO, CA / ACCESS Newswire / September 23, 2025 / Enviro Tech, an Arxada company, ...

Xenex Receives Health Canada Registration for LightStrike6 UV Robot; First & Only UVC Technology Authorized for Healthcare Use Across North America

Xenex Disinfection Services today announced that its LightStrike6(TM) (LS6) UV-C whole room sanitizing robot has received Registration from Health Canada for sale and distribution to healthcare ...
Nanowerk

A leap forward in transparent antimicrobial coatings

Researchers discover remarkable antiviral, antibacterial, and antifungal activity in hydrogen boride nanosheets. (Nanowerk News) The global fight against infectious diseases faces two major challenges ...

Prokaryotics and Basilea enter collaboration to develop a novel broad-spectrum antifungal for severe invasive infections

Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives, today announced an agreement with Basilea Pharmaceutica Ltd, Allschwil ...